InterCure Ltd.
$0.75
▼
-1.73%
2026-04-21 07:30:01
www.intercure.co
NGM: INCR
Explore InterCure Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$125.93 M
Current Price
$0.75
52W High / Low
$605 / $225.3
Stock P/E
—
Book Value
$7.59
Dividend Yield
—
ROCE
-8.41%
ROE
-16.68%
Face Value
—
EPS
$-0.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
320
Beta
0.33
Debt / Equity
41.49
Current Ratio
1.85
Quick Ratio
1.18
Forward P/E
-0.52
Price / Sales
—
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tilray Brands, Inc. | $7.15 | — | $833.32 M | — | -6.01% | -63.16% | $23.2 / $3.51 | $14.89 |
| 2. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 3. | Alkermes plc | $34.23 | 23.69 | $5.73 B | — | 13.07% | 14.72% | $36.48 / $25.16 | $10.99 |
| 4. | ANI Pharmaceuticals, Inc. | $81.73 | 23.13 | $1.81 B | 0.06% | 6.99% | 16.16% | $99.5 / $56.71 | $25.8 |
| 5. | Apimeds Pharmaceuticals US, Inc. | $1.88 | — | $23.64 M | — | 126.09% | 209.61% | $40.31 / $1.61 | $0.65 |
| 6. | Neurocrine Biosciences, Inc. | $130.77 | 28.05 | $13.18 B | — | 16.37% | 16.38% | $160.18 / $98.95 | $32.5 |
| 7. | Sonoma Pharmaceuticals, Inc. | $2.65 | — | $4.59 M | — | -38.66% | -81.18% | $6.92 / $2 | $1.98 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 238.84 M | 355.55 M | 388.68 M | 219.68 M |
| Operating Profit | -45.06 M | 37.59 M | 41.2 M | 33.02 M |
| Net Profit | -67.8 M | -61.96 M | 44.82 M | 4.69 M |
| EPS in Rs | -1.24 | -1.13 | 0.82 | 0.09 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 762.57 M | 786.61 M | 958.01 M | 696.54 M |
| Total Liabilities | 364.9 M | 329.55 M | 436.53 M | 227.13 M |
| Equity | 396.97 M | 455.11 M | 501.31 M | 448.03 M |
| Current Assets | 391.8 M | 418.8 M | 527.49 M | 336.16 M |
| Current Liabilities | 226.75 M | 225.87 M | 312.72 M | 193.59 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -66.93 M | -53.63 M | 51.27 M | 30.14 M |
| Investing CF | 17.69 M | 4.77 M | -142.5 M | -65.21 M |
| Financing CF | 26.45 M | -82.89 M | 120.45 M | 197.94 M |
| Free CF | -71.3 M | -56.25 M | 31.52 M | 16.11 M |
| Capex | -4.38 M | -2.62 M | -19.74 M | -14.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -32.82% | -8.52% | 76.93% | — |
| Earnings Growth % | -9.42% | -238.24% | 855.63% | — |
| Profit Margin % | -28.38% | -17.43% | 11.53% | 2.13% |
| Operating Margin % | -18.86% | 10.57% | 10.6% | 15.03% |
| Gross Margin % | 12.66% | 29.56% | 39.9% | 41.48% |
| EBITDA Margin % | -21.48% | -6.72% | 18.07% | 14.19% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.